secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K/A
Filed at:   2023-12-27T23:59:59+00:00
Accession:  0001213900-23-098928
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix issues $75M in stock for Proteomedix; prior holders diluted to 5.4%
-----------------------------------------------------------------------------

- Onconetix issued 3,675,414 common shares (19.9% of outstanding) and 2,696,729 Series B convertible shares (convertible into 269,672,900 common) for Proteomedix.
- Aggregate consideration valued at ~$75M; Tungsten Advisors received $7.5M in Exchange Shares as compensation.
- Post-closing common outstanding: 22,061,746; after conversion, pre-closing stockholders will own ~5.4%.
- Lock-up of 6 months after stockholder approval; Series B converts automatically or cash settles by Jan 1, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390023098928/0001213900-23-098928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390023098928/ea190756-8ka1_onconetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-098928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer